This study is open to adults with non-cystic fibrosis bronchiectasis. The main purpose of
this study is to find out how a medicine called BI 1323495 is tolerated by people with
The study tests 2 different doses of BI 1323495. Some of the participants get placebo. It is
decided by chance who gets BI 1323495 and who gets placebo. Participants take BI 1323495 or
placebo as tablets twice a day for 3 months. Placebo tablets look like BI 1323495 tablets but
do not contain any medicine. Participants can also continue taking standard medicines for
noncystic bronchiectasis throughout the study.
Participants are in the study for about 4 months. During this time, the participants visit
the study site about 11 times and get about 2 phone calls. At the visits, doctors check the
health of the participants and note any health problems that could have been caused by BI
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.